2026-10-14T22:46:37Z https://data.mendeley.com/oai

oai:data.mendeley.com/cy4mg2gnd3.1 2026-07-14T21:48:14Z

Gellrich, Juliane Soraphen A effect on B cells post-stroke Mendeley Data Introduction: Immunomodulatory approaches could advance post-stroke therapy. Previous work demonstrated that Soraphen A (SorA) improves functional recovery, in part, by modulating T cell responses. Here, we demonstrate that SorA also directly or indirectly modulates B cell responses. Methods: Male Nur77GFP mice (12–14 weeks) underwent tMCAO. At reperfusion, mice received intraperitoneal LPS or vehicle; SorA or vehicle was given 2 h later and daily thereafter. B cell activation and differentiation were analyzed by flow cytometry in lungs, spleen, blood, and lymph nodes at 16 h, 2, 3, and 7 d, with GFP indicating antigen-specific activation. Results: While both SorA and lipopolysaccharide (LPS) replenished splenic B cell numbers depleted by stroke, their effects on B cell subsets diverge. SorA also reversed LPS-induced reductions in lung B cell counts and decreased plasma cell counts. Both treatments increased B cell activation and modulated MHC-II expression. In contrast to T cells, the mode of B cell activation was not affected by SorA treatment. Effects of LPS and SorA on B cell populations were most distinct in the lungs. Discussion: These findings demonstrate that the beneficial effects of SorA after stroke are not solely mediated by T cell modulation. Further investigation into SorA’s organ-specific impact on different B cell subtypes is crucial to fully elucidate its mechanisms of action. Immunology Neurology Neuroimmunology Stroke Ischemic Stroke Dataset doi:10.17632/cy4mg2gnd3.1 oai:data.mendeley.com/cy4mg2gnd3.1 Creative Commons Attribution 4.0 International http://creativecommons.org/licenses/by/4.0 https://data.mendeley.com/datasets/cy4mg2gnd3 2026-07-14T21:48:14Z